Trade Evotec AG - EVT CFD

Add to favourite

13.175

0.68%

0.070

Low: 12.995

High: 13.285

Market Trading Hours* (UTC) Opens on Thursday at 07:00

Mon - Fri: 07:00 - 15:30

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.070

Long position overnight fee

-0.022102%

Short position overnight fee

-0.000121%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

EUR

Margin

Stock exchange

Germany

Commission on trade

*Information provided by Capital.com

Evotec SE ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats

Prev. Close*	13.265
Open*	13.065
1-Year Change*	-31.49%
Day's Range*	12.995 - 13.285
52 wk Range	14.10-24.44
Average Volume (10 days)	1.22M
Average Volume (3 months)	12.25M
Market Cap	2.58B
P/E Ratio	-100.00K
Shares Outstanding	176.94M
Revenue	820.80M
EPS	-0.54
Dividend (Yield %)	N/A
Beta	0.98
Next Earnings Date	N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 17, 2024	13.175	0.050	0.38%	13.125	13.305	12.855
Apr 16, 2024	13.265	-0.170	-1.27%	13.435	13.545	13.135
Apr 15, 2024	13.770	0.190	1.40%	13.580	14.010	13.525
Apr 12, 2024	13.730	-0.050	-0.36%	13.780	14.300	13.600
Apr 11, 2024	13.255	-0.040	-0.30%	13.295	13.605	12.735
Apr 10, 2024	13.465	-0.935	-6.49%	14.400	14.510	13.385
Apr 9, 2024	14.390	0.090	0.63%	14.300	14.550	14.270
Apr 8, 2024	14.480	0.600	4.32%	13.880	14.590	13.810
Apr 5, 2024	13.850	-0.050	-0.36%	13.900	13.910	13.650
Apr 4, 2024	14.070	0.040	0.29%	14.030	14.160	13.790
Apr 3, 2024	14.020	0.010	0.07%	14.010	14.100	13.650
Apr 2, 2024	14.030	-0.280	-1.96%	14.310	14.370	13.930
Mar 28, 2024	14.500	0.205	1.43%	14.295	14.730	14.100
Mar 27, 2024	14.300	0.620	4.53%	13.680	14.420	13.680
Mar 26, 2024	13.770	0.350	2.61%	13.420	13.915	13.270
Mar 25, 2024	13.505	-0.075	-0.55%	13.580	13.620	13.355
Mar 22, 2024	13.650	0.440	3.33%	13.210	13.655	13.210
Mar 21, 2024	13.365	-0.460	-3.33%	13.825	14.000	13.185
Mar 20, 2024	13.600	0.055	0.41%	13.545	13.685	13.395
Mar 19, 2024	13.400	0.355	2.72%	13.045	13.440	12.905

Evotec AG Events

Time (UTC)	Country	Event
Wednesday, April 24, 2024
Time (UTC) 05:00	Country DE	Event Full Year 2023 Evotec SE Earnings Release Full Year 2023 Evotec SE Earnings Release Forecast - Previous -
Time (UTC) 10:59	Country DE	Event Full Year 2023 Evotec SE Earnings Call Full Year 2023 Evotec SE Earnings Call Forecast - Previous -
Wednesday, May 15, 2024
Time (UTC) 10:59	Country DE	Event Evotec SE at Bank of America Health Care Conference Evotec SE at Bank of America Health Care Conference Forecast - Previous -
Wednesday, May 22, 2024
Time (UTC) 05:00	Country DE	Event Q1 2024 Evotec SE Earnings Release Q1 2024 Evotec SE Earnings Release Forecast - Previous -
Time (UTC) 10:59	Country DE	Event Q1 2024 Evotec SE Earnings Call Q1 2024 Evotec SE Earnings Call Forecast - Previous -
Monday, June 10, 2024
Time (UTC) 10:59	Country DE	Event Evotec SE Annual Shareholders Meeting Evotec SE Annual Shareholders Meeting Forecast - Previous -
Wednesday, June 19, 2024
Time (UTC) 10:59	Country DE	Event Evotec SE Annual Shareholders Meeting Evotec SE Annual Shareholders Meeting Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	751.448	618.034	500.924	446.437	375.405
Revenue	751.448	618.034	500.924	446.437	375.405
Cost of Revenue, Total	577.383	466.491	375.181	313.546	263.389
Gross Profit	174.065	151.543	125.743	132.891	112.016
Total Operating Expense	724.824	588.901	452.368	383.843	297.942
Selling/General/Admin. Expenses, Total	156.19	105.445	77.205	66.546	57.012
Research & Development	76.642	72.2	63.945	58.432	35.619
Unusual Expense (Income)	-5.774	12.546	3.244	11.919	-11.036
Other Operating Expenses, Total	-79.617	-67.781	-67.207	-66.6	-47.042
Operating Income	26.624	29.133	48.556	62.594	77.463
Interest Income (Expense), Net Non-Operating	-179.854	208.106	-22.925	-6.102	-5.602
Other, Net	-0.727	-0.259	0.209	0.07	0.138
Net Income Before Taxes	-153.957	236.98	25.84	56.562	71.999
Net Income After Taxes	-175.655	215.51	6.278	37.228	84.056
Minority Interest	0	0	0	0.844	0.116
Net Income Before Extra. Items	-175.655	215.51	6.278	38.072	84.172
Net Income	-175.655	215.51	6.278	38.072	84.172
Income Available to Common Excl. Extra. Items	-175.655	215.51	6.278	38.072	84.172
Income Available to Common Incl. Extra. Items	-175.655	215.51	6.278	38.072	84.172
Diluted Net Income	-175.655	215.51	6.278	38.072	84.172
Diluted Weighted Average Shares	176.674	166.406	153.752	149.726	147.482
Diluted EPS Excluding Extraordinary Items	-0.99423	1.29509	0.04083	0.25428	0.57073
Dividends per Share - Common Stock Primary Issue	0	0	0	0	0
Diluted Normalized EPS	-1.01547	1.36365	0.05455	0.30667	0.52209
Dilution Adjustment					0

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	170.279	213.556	240.689	173.884	172.203
Revenue	170.279	213.556	240.689	173.884	172.203
Cost of Revenue, Total	123.956	160.319	158.233	145.464	141.308
Gross Profit	46.323	53.237	82.456	28.42	30.895
Total Operating Expense	206.567	201.041	197.229	187.413	175.973
Selling/General/Admin. Expenses, Total	45.609	42.583	46.332	42.462	35.83
Research & Development	12.377	18.486	21.322	18.482	18.725
Other Operating Expenses, Total	24.625	-20.347	-22.884	-18.995	-19.89
Operating Income	-36.288	12.515	43.46	-13.529	-3.77
Interest Income (Expense), Net Non-Operating	5.261	-6.203	-60.362	-29.806	-20.131
Other, Net	10.59	-12.527	-0.622	-0.029	-0.435
Net Income Before Taxes	-20.437	-6.215	-17.524	-43.364	-24.336
Net Income After Taxes	-14.929	-13.898	-27.201	-47.275	-27.937
Net Income Before Extra. Items	-14.929	-13.898	-27.201	-47.275	-27.937
Net Income	-14.929	-13.898	-27.201	-47.275	-27.937
Income Available to Common Excl. Extra. Items	-14.929	-13.899	-27.201	-47.275	-27.937
Income Available to Common Incl. Extra. Items	-14.929	-13.899	-27.201	-47.275	-27.937
Diluted Net Income	-14.929	-13.899	-27.201	-47.275	-27.937
Diluted Weighted Average Shares	176.936	176.936	176.589	176.703	176.703
Diluted EPS Excluding Extraordinary Items	-0.08438	-0.07855	-0.15404	-0.26754	-0.1581
Dividends per Share - Common Stock Primary Issue	0	0	0	0	0
Diluted Normalized EPS	-0.08438	-0.07855	-0.17529	-0.26754	-0.1581
Unusual Expense (Income)			-5.774	0	0
Minority Interest			0
Total Adjustments to Net Income		-0.001

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1073.67	1100.94	658.844	469.53	249.769
Cash and Short Term Investments	729.983	858.498	492.634	321.662	149.879
Cash & Equivalents	415.155	699.326	422.58	277.034	109.055
Short Term Investments	314.828	159.172	70.054	44.628	40.824
Total Receivables, Net	256.737	176.754	122.221	117.844	74.772
Accounts Receivable - Trade, Net	199.169	150.692	91.612	93.702	58.851
Total Inventory	29.825	25.793	13.585	10.749	5.66
Prepaid Expenses	40.178	19.21	9.258	9.166	8.451
Other Current Assets, Total	16.948	20.685	21.146	10.109	11.007
Total Assets	2257.25	2235.16	1462.34	1180.91	771.883
Property/Plant/Equipment, Total - Net	650.201	484.597	337.297	239.229	90.519
Property/Plant/Equipment, Total - Gross	920.81	686.086	481.879	350.415	164.143
Accumulated Depreciation, Total	-270.609	-201.489	-144.582	-111.186	-73.624
Goodwill, Net	274.819	257.569	247.37	255.919	220.791
Intangibles, Net	23.819	30.851	98.036	116.994	122.989
Long Term Investments	150.332	287.009	59.021	41.252	28.99
Note Receivable - Long Term	70.293	55.966	36.485	22.718	14.601
Other Long Term Assets, Total	14.112	18.229	25.284	35.27	44.224
Total Current Liabilities	337.706	324.516	208.459	178.955	196.275
Accounts Payable	97.277	72.598	42.549	31.319	31.137
Accrued Expenses	47.49	33.983	34.728	29.174	25.67
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	16.381	50.609	30.008	20.731	56.919
Other Current Liabilities, Total	176.558	167.326	101.174	97.731	82.549
Total Liabilities	1070.06	857.476	737.881	703.883	347.879
Total Long Term Debt	490.293	462.308	461.957	442.368	57.546
Long Term Debt	328.295	326.344	331.019	324.886	54.68
Capital Lease Obligations	161.998	135.964	130.938	117.482	2.866
Deferred Income Tax	18.524	17.688	20.399	21.199	21.517
Minority Interest	0	0	0	0	0.876
Other Liabilities, Total	223.54	52.964	47.066	61.361	71.665
Total Equity	1187.18	1377.69	724.456	477.029	424.004
Common Stock	176.953	176.608	163.915	150.903	149.063
Additional Paid-In Capital	1440.01	1430.14	1030.7	786.865	783.154
Retained Earnings (Accumulated Deficit)	-392.377	-216.421	-432.639	-441.177	-481.013
Unrealized Gain (Loss)	-21.113	3.053	4.26	4.565	6.002
Other Equity, Total	-16.289	-15.691	-41.782	-24.127	-33.202
Total Liabilities & Shareholders’ Equity	2257.25	2235.16	1462.34	1180.91	771.883
Total Common Shares Outstanding	176.703	176.358	163.665	150.653	148.813

	Sep 2023	Jun 2023	Dec 2022	Sep 2022
Total Current Assets	939.198	1026.45	1073.67	1095.82
Cash and Short Term Investments	619.18	632.973	729.983	828.795
Cash & Equivalents	499.366	459.752	415.155	463.913
Short Term Investments	119.814	173.221	314.828	364.882
Total Receivables, Net	219.371	291.301	256.737	187.997
Accounts Receivable - Trade, Net	161.105	228.955	199.169	140.631
Total Inventory	31.906	32.612	29.825	30.874
Prepaid Expenses	68.741	69.563	57.126	48.15
Total Assets	2254.51	2301.22	2257.25	2262.66
Property/Plant/Equipment, Total - Net	763.899	721.136	650.201	600.499
Goodwill, Net			274.819	278.417
Intangibles, Net	291.055	292.612	23.819	25.736
Long Term Investments	151.62	160.842	150.332	189.245
Note Receivable - Long Term	98.685	88.8	70.293	56.911
Other Long Term Assets, Total	10.052	11.382	14.112	16.039
Total Current Liabilities	434.045	488.107	337.706	340.802
Accounts Payable	96.774	106.038	97.277	83.965
Notes Payable/Short Term Debt	0	0	0	0
Current Port. of LT Debt/Capital Leases	144.287	151.638	16.381	14.108
Other Current Liabilities, Total	192.984	230.431	224.048	242.729
Total Liabilities	1113.69	1126.93	1070.06	1034.14
Total Long Term Debt	444.455	382.509	490.293	477.984
Long Term Debt	444.455	382.509	328.295	326.776
Capital Lease Obligations			161.998	151.208
Deferred Income Tax	18.603	19.13	18.524	17.179
Other Liabilities, Total	216.587	237.188	223.54	198.173
Total Equity	1140.82	1174.29	1187.18	1228.53
Common Stock	177.186	177.186	176.953	176.953
Additional Paid-In Capital	1446.47	1445.36	1440.01	1437.55
Retained Earnings (Accumulated Deficit)	-482.836	-448.256	-392.377	-364.631
Other Equity, Total			-16.289	-21.348
Total Liabilities & Shareholders’ Equity	2254.51	2301.22	2257.25	2262.66
Total Common Shares Outstanding	176.936	176.936	176.703	176.703
Unrealized Gain (Loss)			-21.113
Minority Interest	0	0	0	0
Other Current Assets, Total				0.001

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-175.655	215.51	6.252	37.228	84.056
Cash From Operating Activities	203.106	122.237	44.721	42.216	156.24
Cash From Operating Activities	72.677	55.596	42.122	36.456	19.288
Amortization	8.982	12.012	13.936	12.349	12.005
Deferred Taxes	7.722	5.066	7.49	6.706	-26.117
Non-Cash Items	195.391	-165.371	23.865	24.342	0.364
Cash Taxes Paid	18.5	-6.028	9.796	2.417	3.596
Cash Interest Paid	9.798	5.429	3.465	4.49	2.279
Changes in Working Capital	93.989	-0.576	-48.944	-74.865	66.644
Cash From Investing Activities	-415.823	-243.855	-155.089	-86.634	-39.13
Capital Expenditures	-181.354	-118.943	-99.072	-31.905	-27.867
Other Investing Cash Flow Items, Total	-234.469	-124.912	-56.017	-54.729	-11.263
Cash From Financing Activities	-52.414	398.43	246.409	211.263	-77.764
Financing Cash Flow Items
Issuance (Retirement) of Stock, Net	0.699	404.322	251.564	1.901	1.578
Issuance (Retirement) of Debt, Net	-53.113	-5.892	-5.155	209.362	-79.342
Foreign Exchange Effects	-19.04	-0.066	9.505	1.134	2.692
Net Change in Cash	-284.171	276.746	145.546	167.979	42.038

	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021
Net income/Starting Line	-175.655	-148.454	-101.179	-73.242	215.51
Cash From Operating Activities	203.106	236.633	240.607	63.618	122.237
Changes in Working Capital	378.761	385.087	341.786	136.86	-93.273
Cash From Investing Activities	-415.823	-435.034	-206.857	-95.732	-243.855
Capital Expenditures	-181.354	-157.21	-81.371	-42.921	-118.943
Other Investing Cash Flow Items, Total	-234.469	-277.824	-125.486	-52.811	-124.912
Cash From Financing Activities	-52.414	-50.454	-45.805	-5.279	398.43
Issuance (Retirement) of Stock, Net	0.699	0.355	0.7	0.345	404.322
Issuance (Retirement) of Debt, Net	-53.113	-50.809	-46.505	-5.624	-5.892
Foreign Exchange Effects	-19.04	13.442	9.721	-1.445	-0.066
Net Change in Cash	-284.171	-235.413	-2.334	-38.838	276.746

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Evotec Company profile

About Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Evotec SE revenues increased 20% to EUR431M. Net income increased from EUR5.8M to EUR247M. Revenues reflect EVT Execute segment increase of 22% to EUR329M, EVT Innovate segment increase of 36% to EUR101.9M, United States segment increase of 32% to EUR142.9M, Others segment increase of 30% to EUR47.5M, United Kingdom segment increase of 8% to EUR47.2M.

Industry:

Biotechnology & Medical Research (NEC)

Essener Bogen 7
HAMBURG
HAMBURG 22419
DE

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024